Chris Ryan

Chris Ryan joined OncLive in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

FDA Accepts NDA For 177Lu-edotreotide for GEP-NETs

November 13th 2025

The NDA seeking approval of 177Lu-edotreotide for the treatment of patients with GEP-NETs has been accepted by the FDA.

FDA Approves Ziftomenib for NPM1+ R/R Acute Myeloid Leukemia

November 13th 2025

Ziftomenib has received FDA approval for the treatment of adult patients with relapsed or refractory acute myeloid leukemia harboring an NPM1 mutation.

MB-105 Receives FDA RMAT Designation in CD5+ R/R T-Cell Lymphoma

November 13th 2025

The FDA granted RMAT designation to MB-105 for CD5-positive relapsed/refractory T-cell lymphoma.

Community Administration of Bispecific Antibodies in Myeloma Hinges on Consensus and Guidance

November 13th 2025

Experts discuss considerations surrounding the integration of bispecific antibodies in community oncology for multiple myeloma.

Emerging ADC Data and Combination Strategies Are Set to Redefine First-Line TNBC Management

November 12th 2025

Joyce O'Shaughnessy, MD, discusses ways that data with sacituzumab govitecan and Dato-DXd may shift treatment standards for patients with mTNBC.

Tinostamustine Snags FDA Orphan Drug Designation for Malignant Glioma

November 12th 2025

The FDA granted orphan drug designation to tinostamustine for malignant glioma.

FDA Grants Fast Track Designation to AVZO-1418/DB-1418 for EGFR+, TKI-Pretreated NSCLC

November 12th 2025

AVZO-1418/DB-1418 has received fast track designation from the FDA for patients with advanced, EGFR-mutant NSCLC following prior therapy with an EGFR TKI.

Sequential CAR T-Cell Therapy and ASCT Yields Durable Remissions in Ph-Negative B-ALL

November 12th 2025

Phase 2 data showed high 2-year survival and deep MRD-negative remissions with a CD22/CD19 CAR T-cell therapy and ASCT “sandwich” approach in B-ALL.

CONGRATS Trial Data of Nivolumab ± Relatlimab Highlight Clinical Value of Immunotherapy in TLS+ Soft Tissue Sarcoma

November 11th 2025

Nivolumab with or without relatlimab exceeded historical benchmarks in TLS-positive soft tissue sarcoma, validating TLS as a predictive biomarker.

Lutetium Lu 177 Vipivotide Tetraxetan Enables Some Patients with mCRPC to Avoid Chemotherapy

November 10th 2025

Daniel J. George, MD, discusses the role of lutetium Lu 177 vipivotide tetraxetan in metastatic CRPC and patient selection considerations.

Pharmacists Play Key Role in Patient Education and Treatment Adherence in CML Management

November 10th 2025

Jose Tinajero, PharmD, BCOP, discusses the role of the pharmacist in treatment planning and management in chronic myeloid leukemia.

Evolving Post–CDK4/6 Inhibitor Strategies Reflect Need for Precision Approaches in HR+ Breast Cancer

November 10th 2025

Kevin Kalinsky, MD, MS, FASCO, discusses treatments and targeted therapies in the post–CDK4/6 inhibitor setting of HR+ breast cancer.

First-Line Sacituzumab Govitecan After Endocrine Therapy Fails to Improve PFS in HR+/HER2-Negative Breast Cancer

November 7th 2025

The phase 3 ASCENT-07 trial did not meet its primary PFS end point with first-line sacituzumab govitecan in hormone receptor–positive, HER2-negative breast cancer.

FDA Approves Generic Dasatinib Tablets for CML, ALL

November 7th 2025

The FDA has approved generic dasatinib tablets for select patients with chronic myeloid leukemia and acute lymphoblastic leukemia.

Darovasertib Plus Crizotinib Could Represent Systemic Therapy Intended for Broader Metastatic Uveal Melanoma Population

November 7th 2025

Marlana Orloff, MD, discusses data for the combination of darovasertib and crizotinib in metastatic uveal melanoma.

FDA Approves Subcutaneous Daratumumab for High-Risk Smoldering Multiple Myeloma

November 6th 2025

The FDA has approved daratumumab and hyaluronidase-fihj for the treatment of adult patients with high-risk smoldering multiple myeloma.

GFH375 Yields Responses, Disease Control in Heavily Pretreated KRAS G12D+ PDAC

November 6th 2025

GFH375 produced responses and tumor shrinkage in heavily pretreated pancreatic ductal adenocarcinoma harboring KRAS G12D mutations.

ChatGPT Fails to Provide Up-to-Date and Specific Information for Specific Queries in Hematologic Malignancies

November 6th 2025

Justin Taylor, MD, discusses findings from a study that evaluated the ability of ChatGPT to offer specific information in hematologic malignancies.

Oncology Fellows Spotlights Recent Grant and Award Winners

November 6th 2025

Oncology Fellows reports recent hematology/oncology fellows grant and award winners and looks ahead to upcoming grants.

177Lu-edotreotide Displays Efficacy Benefit Across Subgroups in Grade 1/2, SSTR+ GEP-NETs

November 6th 2025

Treatment with 177Lu-edotreotide was linked to improvements in PFS and ORR across subgroups of patients with SSTR-positive GEP-NETs.